| Trial-Results center | |||
| Clinical trial results database |
 Feedback
 Home
|
This trial is included in the following systematic reviews and meta-analyses:
coronary artery disease
-
myocardial revascularization
-
all type of patient
stable angina
-
myocardial revascularization
-
all type of patient
coronary artery disease
-
revascularization with drug eluting stent
-
all type of patients
coronary artery disease
-
revascularization with drug eluting stent
-
unparticular patients
Related trials
SPIRIT IV, 2010 - everolimus ES vs paclitaxel ES
SORT-OUT-3, 2010 - zotarolimus ES vs sirolimus ES
ISAR-DESIRE-2, 2010 - sirolimus ES vs paclitaxel ES
RESOLUTE, 2010 - zotarolimus ES vs everolimus ES
ZEST (vs PES), 2009 - zotarolimus ES vs paclitaxel ES
PASEO, 2009 - drug ES vs bare-metal stent
Thiele, 2009 - sirolimus ES vs MIDCAB
ISAR TEST 2 (vs ZES), 2009 - dual sirolimus, probucol ES vs zotarolimus ES
ISAR TEST 3 (PF), 2009 - polymer free sirolimus stent vs sirolimus ES
ENDEAVOR IV, 2009 - zotarolimus ES vs paclitaxel ES
GENIUS-STEMI, 2009 - Genous stent vs bare-metal stent
ZEST AMI (vs PES), 2009 - zotarolimus ES vs paclitaxel ES
STICH (ventricular reconstruction), 2009 - CABG+surgical ventricular reconstruction vs CABG
ISAR TEST 2 (vs SES), 2009 - dual sirolimus, probucol ES vs sirolimus ES
COMPARE, 2009 - everolimus ES vs paclitaxel ES
ISAR TEST 3 (BP), 2009 - biodegradable-polymer sirolimus stent vs sirolimus ES
ZEST (vs SES), 2009 - zotarolimus ES vs sirolimus ES
ZEST AMI (vs SES), 2009 - zotarolimus ES vs sirolimus ES
BARI 2D, 2009 - CABG or PCI vs medical treatment
DEBATER (SES vs BMS), 2009 - sirolimus ES vs bare-metal stent
ISAR-TEST-4, 2009 - sirolimus biodegradable polymer vs sirolimus ES
SYNTAX, 2009 - paclitaxel ES vs CABG
ISAR-LEFT-MAIN, 2009 - sirolimus ES vs paclitaxel ES
See also:
RES-I study, 2010 |
|
| [NCT00606333] | |
Treatments
| Studied treatment |
Nevo Cobalt Chromium Sirolimus-reservoir eluting Coronary Stent System
Nevo cobalt-chromium stent dotted with reservoirs |
| Control treatment |
TAXUS Liberte Paclitaxel-eluting Coronary Stent System
|
Patients
| Patients | De Novo Native Coronary Artery Lesions with length of 28 mm or less and range in diameter from 2.5 to 3.5 mm |
Method and design
| Randomized effectives | 202 / 192 (studied vs. control) |
| Design | Parallel groups |
| Blinding | open |
| Follow-up duration | 1 y |
| Number of centre | 40 |
| Geographic area | Europe, Brazil, Australia, New Zealand |
| Primary endpoint | late loss |
Results
No results available for this trial - no clinical endpoint reported
Reference(s)
| Trials register # | NCT00606333 |
| Study web site link | , |
External links about this trial
(c) 2004-2010 TrialResults-center - All Rights Reserved
Tweet this
notify a friend